Chronic Inflammatory Demyelinating Polyneuropathy Market Trends Highlight Clinical Trials, FDA Activity, and Global Market Expansion

"The global chronic inflammatory demyelinating polyneuropathy market size reached US$2.02 billion in 2024 and is expected to reach US$5.07 billion by 2033, growing at a CAGR of 9.7% during the forecast period 2025-2033," according to DataM Intelligence.

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is led by major players such as Grifols, CSL Behring, Octapharma, Baxter, and Kedrion S.p.A., who dominate the immunoglobulin therapy segment. Companies like Bio Products Laboratory Ltd, Shire, and Momenta Pharmaceuticals are expanding their neurology pipelines through innovation and partnerships. Mitsubishi Tanabe Pharma, Teijin Pharma, and Pfizer Inc. are advancing biologic and immunomodulatory treatments.

Download your exclusive sample report today: https://www.datamintelligence.com/download-sample/chronic-inflammatory-demyelinating-polyneuropathy-market?jd

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market M&A & Strategic Collaborations

1. argenx & Zai Lab partnership advancing Vyvgart Hytrulo launch in China
In May 2025, argenx SE and Zai Lab extended their collaboration to support the introduction of Vyvgart Hytrulo, the first subcutaneous FcRn blocker approved for CIDP, into Chinese clinics, aiming to improve treatment convenience and patient access in Greater China.

2. Takeda's GAMMAGARD LIQUID FDA label expansion
In January 2024, Takeda secured FDA approval for GAMMAGARD LIQUID as an IVIG therapy for adult CIDP, with expanded use gaining traction in early 2025 across North America and Europe under national immunoglobulin supply networks.

3. Argenx's Vyvgart Hytrulo boosts clinic readiness
In June 2025, ar¬genx's subcutaneous treatment received momentum in North America following strong real-world outcomes in the ADHERE trial, facilitating new partnerships with infusion centers and health providers for broader rollout.

As per our analysis, these developments underscore the CIDP market's emphasis on therapeutic innovation, label expansions, and cross-border market strategies.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/chronic-inflammatory-demyelinating-polyneuropathy-market?jd

Key Growth Drivers & Emerging Opportunities in the CIDP Market

• The rising global prevalence of autoimmune neuropathies is increasing demand for long-term CIDP management solutions.
• Advancements in immunoglobulin and FcRn-targeted therapies (e.g., Vyvgart Hytrulo) are reshaping treatment approaches.
• Improved diagnostic capabilities and earlier disease detection are expanding the eligible patient population.
• Ongoing clinical trials in monoclonal antibodies, subcutaneous therapies, and corticosteroid alternatives are opening new market opportunities.
• Strategic partnerships in emerging markets are enhancing access to CIDP therapies through localized production and distribution.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=chronic-inflammatory-demyelinating-polyneuropathy-market?jd

Regional Market Drivers for the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

North America leads the market due to strong reimbursement systems, high awareness of rare neurological disorders, and early adoption of IVIG and emerging biologics.

Europe benefits from government-funded treatment programs, centralized immunoglobulin supply chains, and robust rare disease surveillance systems.

Asia-Pacific is experiencing rapid growth with increased healthcare access, improving neurology diagnostics, and rising investments in autoimmune disorder research.

Latin America is driven by improving healthcare infrastructure and growing availability of immunoglobulin therapies through international health partnerships.

Middle East & Africa show steady progress due to expanding specialist care facilities and global aid programs supporting rare disease treatment access.

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.